NCT02788253 is a clinical trial in Intubation; Difficult, sponsored by University Hospital, Caen.

Who is sponsoring NCT02788253?

NCT02788253 is sponsored by University Hospital, Caen.

What condition does NCT02788253 study?

NCT02788253 studies Intubation; Difficult.

Is NCT02788253 still recruiting?

NCT02788253 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT02788253

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mallampati Classification vs Best Visible Mallampati for Prediction of Difficult Tracheal Intubation

Completed Last updated 8 February 2023

What this trial tests

trial in Intubation; Difficult in 3,244 participants. Completed in 31 December 2019.

Timeline

1 June 2017

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	University Hospital, Caen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,244
Start date	1 June 2017
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across France

Conditions studied

Intubation; Difficult — all drugs for Intubation; Difficult →

Sponsor

University Hospital, Caen

Who can join

16 and older, any sex, with Intubation; Difficult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mallampati score (classification of the visibility of oropharyngeal structures) should be performed in the sitting position, head in the neutral position, mouth widely open, and tongue protrudes, without phonation. However, phonation, and position modify the visibility of oropharyngeal structures and thus the Mallampati score. We aimed at evaluating the predictive value of the best observable Mallampati score as compare to the recommended Mallampati score.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of the modified Mallampati classification score versus the best visible Mallampati score in the prediction of difficult tracheal intubation: a single-centre prospective observational study.
Hanouz JL, Lefrançois V, Boutros M, Fiant AL, et al · · 2024 · PMID 39147992 · DOI 10.1007/s12630-024-02815-0

Verify or expand the search:

Other University Hospital, Caen trials

Trials by the same sponsor.

NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02788253 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02788253.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing